Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols

References

• de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008;111(7):3395–3402.
   PubMed Web of Science ®Google Scholar
• Iland HJ, Collins M, Bradstock K, et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian leukaemia and lymphoma group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematol. 2015;2(9):e357-366–e366.
   Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111–121.
   PubMed Web of Science ®Google Scholar
• Cicconi L, Platzbecker U, Avvisati G, et al. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. Leukemia. 2020;34(3):914–918.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Avvisati G, Cicconi L, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in Non-High-Risk acute promyelocytic leukemia: Final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2017;35(6):605–612.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the european LeukemiaNet. Blood. 2019;133(15):1630–1643.
   PubMed Web of Science ®Google Scholar
• Gurnari C, De Bellis E, Divona M, et al. When poisons cure: the case of arsenic in acute promyelocytic leukemia. Chemotherapy. 2019;64(5-6):238–247.
   PubMed Web of Science ®Google Scholar
• Kayser S, Rahmé R, Martínez-Cuadrón D, et al. Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an international collaborative study. Leukemia. 2020;34(9):2333–2341.
   PubMed Web of Science ®Google Scholar
• Ferrara F, Finizio O, D'Arco A, et al. Acute promyelocytic leukemia in patients aged over 60 years: multicenter experience of 34 consecutive unselected patients. Anticancer Res. 2010;30(3):967–971.
   PubMed Web of Science ®Google Scholar
• Salamero O, Martínez-Cuadrón D, Sobas M, PETHEMA and PALG Groups, et al. Real life outcomes of patients aged ≥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry. Leuk Lymphoma. 2019;60(11):2720–2732.
   PubMed Web of Science ®Google Scholar
• Ades L, Chevret S, De Botton S, et al. Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the european group experience. Leukemia. 2005;19(2):230–233.
   PubMed Web of Science ®Google Scholar
• Borlenghi E, Cattaneo C, Schieppati F, et al. Acute promyelocytic leukemia in patients aged >70 years is not rare and highly curable: a single center series of 21 unselected patients. Leuk Lymphoma. 2019;60(2):531–534.
   PubMed Web of Science ®Google Scholar
• Martínez-Cuadrón D, Montesinos P, Vellenga E, et al. Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy. Leukemia. 2018;32(1):21–29.
   PubMed Web of Science ®Google Scholar
• Latagliata R, Breccia M, Fazi P, et al. GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. Br J Haematol. 2011;154(5):564–568.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(13):1295–1305.
   PubMed Web of Science ®Google Scholar
• Walter RB, Othus M, Burnett AK, et al. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD anderson cancer center. Leukemia. 2015;29(2):312–320.
   PubMed Web of Science ®Google Scholar
• Sun J, Zhu J, Zhou D, et al. Factors affecting early death and survival of patients with acute promyelocytic leukemia treated with ATRA-Based therapy regimens. Clin Lymph Myel Leuk. 2019;19(1):e63–e70.
   PubMed Web of Science ®Google Scholar
• Disperati P, Minden MD, Gupta V, et al. Acute promyelocytic leukemia in patients aged 70 years and over - a single center experience of unselected patients. Leuk Lymphoma. 2007;48(8):1654–1658.
   PubMed Web of Science ®Google Scholar
• Gurnari C, Breccia M, Di Giuliano F, et al. Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters. Br J Haematol. 2021;193(1):129–1111. /bjh.17018.
   PubMed Web of Science ®Google Scholar
• Lehmann S, Ravn A, Carlsson L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the swedish adult acute leukemia registry. Leukemia. 2011;25(7):1128–1134.
   PubMed Web of Science ®Google Scholar
• Martinez-Cuadron D, Sobas M, Vellenga E, et al. Incidence and risk factors for early death among 2421 APL patients: the PETHEMA registry experience. HemaSphere. 2019;3(S1):78–79.
   PubMed Web of Science ®Google Scholar
• Naymagon L, Moshier E, Tremblay D, et al. Predictors of early hemorrhage in acute promyelocytic leukemia. Leuk Lymphoma. 2019;60(10):2394–2403.
   PubMed Web of Science ®Google Scholar
• Sham RL, Tallman MS. Treatment of acute promyelocytic leukemia in the very elderly: case report and review of the literature. Leuk Res. 2004;28(12):1347–1350.
   PubMed Web of Science ®Google Scholar
• Rahmé R, Ades L, Thomas X, et al. Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the french belgian swiss APL group (APL 2006 trial). Haematologica. 2018;103(11):e519–e521.
   PubMed Web of Science ®Google Scholar
• Ono T, Takeshita A, Kishimoto Y, et al. Long-term outcome and prognostic factors of elderly patients with acute promyelocytic leukemia. Cancer Sci. 2012;103(11):1974–1978.
   PubMed Web of Science ®Google Scholar
• Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British cooperative group. Ann Intern Med. 1985;103(4):620–625.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573–577.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA group. Blood. 2010;116(17):3171–3179.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Lo Coco F, Martín G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96:1247–1253.
   PubMed Web of Science ®Google Scholar
• Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649–655.
   PubMed Web of Science ®Google Scholar
• Lengfelder E, Hofmann WK, Nolte F. Management of elderly patients with acute promyelocytic leukemia: progress and problems. Ann Hematol. 2013;92(9):1181–1188.
   PubMed Web of Science ®Google Scholar
• Jácomo RH, Melo RA, Souto FR, et al. Clinical features and outcomes of 134 brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica. 2007;92(10):1431–1432.
   PubMed Web of Science ®Google Scholar
• Ghavamzadeh A, Alimoghaddam K, Rostami S, et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol. 2011;29(20):2753–2757.
   PubMed Web of Science ®Google Scholar
• Wedding U, Ködding D, Pientka L, et al. Physicians' judgement and comprehensive geriatric assessment (CGA) select different patients as fit for chemotherapy. Crit Rev Oncol Hematol. 2007;64(1):1–9.
   PubMed Web of Science ®Google Scholar
• Klepin HD, Neuendorff NR, Larson RA, et al. Treatment of acute promyelocytic leukemia in older patients: recommendations of an international society of geriatric oncology (SIOG) task force. J Geriatr Oncol. 2020;11(8):1199–1209.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Z, Li J, et al. Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia. Cancer. 2013;119(1):115–125.
   PubMed Web of Science ®Google Scholar